OrganoClick (ORGC) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 were SEK 35.4 million, a decrease of 7.3% year-over-year, with operating loss (EBIT) of SEK -2.1 million and a net loss of SEK -3.6 million.

• Consumer brands OrganoTex and BIOkleen gained new major retailers in Sweden and Europe, while industrial product segments faced continued market headwinds and price pressure.

• Gross margin declined to 25.2% from 29.3% due to lower revenues and product mix, with cash flow from operating activities at SEK -10.5 million.

Financial highlights

• Revenue fell 7.3% year-over-year to SEK 35.4 million; gross profit was SEK 8.9 million, down from SEK 11.2 million.

• EBIT was SEK -2.1 million (Q1 2024: SEK 0.2 million); EBITDA was SEK 2.0 million (Q1 2024: SEK 4.2 million).

• Earnings per share were SEK -0.04 (Q1 2024: SEK -0.02).

• Cash and cash equivalents at period end were SEK 0.4 million, with a quick ratio of 33.3%.

• Net debt/equity ratio rose to 311.3% from 138.6% year-over-year.

Outlook and guidance

• Consumer products BIOkleen and OrganoTex are expected to continue strong performance, supported by expanded retail partnerships.

• Focus remains on new customer sales and advancing industrial customer projects to drive growth by 2026.

• Ongoing R&D aims to improve biobased binder competitiveness versus fossil-based alternatives.